基于增强CT鉴别非富血供胰腺神经内分泌肿瘤与CA19-9阴性胰腺导管腺癌:大样本系列研究
本回顾性研究纳入134例病理证实的非富血供胰腺神经内分泌肿瘤与128例CA19-9阴性胰腺导管腺癌,均术前接受增强CT检查。多因素分析显示,无局部侵犯、无胰周血管侵犯、远端主胰管直径正常、无区域淋巴结肿大及肿瘤不均匀强化是非富血供PNEN的显著预测因素,影像特征模型AUC为0.829。作者认为增强CT定性特征有助于两者鉴别。
要点
- 非富血供PNEN较CA19-9阴性PDAC更常见边界清晰和钙化,更少出现局部侵犯和胰周血管侵犯。
- 无局部侵犯(OR=0.233)、无胰周血管侵犯(OR=0.434)、远端主胰管直径正常(OR=0.398)是非富血供PNEN的独立预测因素。
- 无区域淋巴结肿大(OR=0.455)和肿瘤不均匀强化(OR=0.240)亦为非富血供PNEN的独立预测因素,影像特征模型AUC为0.829。
核心结论
- 增强CT定性特征有助于鉴别非富血供PNEN与CA19-9阴性PDAC,基于逻辑回归的影像特征模型AUC为0.829。
研究设计与样本
- 回顾性研究,纳入134例病理证实的非富血供PNEN和128例CA19-9阴性PDAC,均于2015年1月至2024年3月术前接受增强CT检查,由两名放射科医师独立评估动脉期和门静脉期定性特征。
关键影像表现/征象
- 非富血供PNEN较CA19-9阴性PDAC更常见边界清晰(p<0.001)和钙化(p=0.032)。
- 非富血供PNEN较CA19-9阴性PDAC更少出现局部侵犯(p<0.001)和胰周血管侵犯(p=0.001)。
- 非富血供PNEN较CA19-9阴性PDAC更少出现肝内或肝外胆管扩张(p<0.001)和远端主胰管扩张(p<0.001)。
- 非富血供PNEN较CA19-9阴性PDAC更少出现区域淋巴结肿大(p<0.001),肿瘤均匀强化频率更低(p<0.001)。
诊断标准与关键数值
- 多因素分析显示,无局部侵犯(OR=0.233,95%CI 0.114-0.476,p<0.001)是非富血供PNEN的显著预测因素。
- 无胰周血管侵犯(OR=0.434,95%CI 0.217-0.870,p=0.019)是非富血供PNEN的显著预测因素。
- 远端主胰管直径正常(OR=0.398,95%CI 0.202-0.785,p=0.008)是非富血供PNEN的显著预测因素。
- 无区域淋巴结肿大(OR=0.455,95%CI 0.238-0.870,p=0.017)是非富血供PNEN的显著预测因素。
- 肿瘤不均匀强化(OR=0.240,95%CI 0.126-0.456,p<0.001)是非富血供PNEN的显著预测因素,影像特征模型AUC为0.829。
临床应用与阅片要点
- 在CA19-9正常或阴性的人群中,可依据边界清晰、钙化、无局部侵犯、无胰周血管侵犯、远端主胰管不扩张、无区域淋巴结肿大及肿瘤不均匀强化等征象,鉴别非富血供PNEN与PDAC。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PROPOSE: This study aims to evaluate the effectiveness of contrast-enhanced computed tomography (CT) in distinguishing non-hypervascular pancreatic neuroendocrine neoplasms (PNENs) from pancreatic ductal adenocarcinomas (PDACs) with a normal serum level of carbohydrate antigen 19-9 (CA19-9) levels.
METHODS: This retrospective study included 134 patients with pathologically confirmed non-hypervascular PNENs and 128 patients with CA19-9-negative PDACs, all of whom underwent contrast-enhanced CT prior to surgery between January 2015 and March 2024. Following independent evaluation by two radiologists, qualitative features from both groups were extracted in the arterial and portal venous phase and subsequently compared using univariate and multivariate analysis.
RESULTS: Patients with CA19-9 negative PDACs were significantly older than those with non-hypervascular PNENs (p < 0.001), and the majority of PDACs were located in the head of the pancreas (p < 0.01).Univariate analysis showed that non-hypervascular PNENs exhibited a higher frequency of well-defined tumor margins (p < 0.001) and calcification (p = 0.032) and a lower frequency of local invasion (p < 0.001), peripancreatic vascular invasion (p = 0.001), intra- or extrahepatic bile duct dilatation (p < 0.001), distal main pancreatic duct dilatation (p < 0.001), regional lymphadenopathy (p < 0.001) and tumor homogeneity (p < 0.001) when compared to CA19-9 negative PDACs. Multivariate analysis identified the absence of local invasion (Odds Ratio (OR) = 0.233; 95 % Confidence Internals (95 % CI):0.114-0.476; p < 0.001), absence of peripancreatic vascular invasion (OR = 0.434; 95 % CI:0.217-0.870; p = 0.019), a normal distal main pancreatic duct diameter (OR = 0.398; 95 % CI:0.202-0.785; p = 0.008), absence of regional lymphadenopathy (OR = 0.455; 95 % CI:0.238-0.870; p = 0.017) and tumor heterogeneity (OR = 0.240; 95 % CI:0.126-0.456; p < 0.001) as significant predictors of non-hypervascular PNENs. The area under the receiver operating characteristic curve for the radiological feature model was 0.829 based on logistic regression.
CONCLUSIONS: Qualitative features in contrast-enhanced CT images could be beneficial in differentially diagnosing non-hypervascular PNENs and CA19-9 negative PDACs.
引用
- Zhang J, Tan Q, Fan Y, et al. Non-hypervascular pancreatic neuroendocrine neoplasms differentiation from CA19-9 negative pancreatic ductal adenocarcinomas based on contrast CT: A large sample series. Eur J Radiol. 2025. PMID: 40209484. doi:10.1016/j.ejrad.2025.112095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。